Asset Details
Do you wish to reserve the book?
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
Do you wish to request the book?
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
2020
Overview
Drug combinations are becoming a standard treatment of many complex diseases due to their capability to overcome resistance to monotherapy. In the current preclinical drug combination screening, the top combinations for further study are often selected based on synergy alone, without considering the combination efficacy and toxicity effects, even though these are critical determinants for the clinical success of a therapy. To promote the prioritization of drug combinations based on integrated analysis of synergy, efficacy and toxicity profiles, we implemented a web-based open-source tool, SynToxProfiler (Synergy-Toxicity-Profiler). When applied to 20 anti-cancer drug combinations tested both in healthy control and T-cell prolymphocytic leukemia (T-PLL) patient cells, as well as to 77 anti-viral drug pairs tested in Huh7 liver cell line with and without Ebola virus infection, SynToxProfiler prioritized as top hits those synergistic drug pairs that showed higher selective efficacy (difference between efficacy and toxicity), which offers an improved likelihood for clinical success.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - toxicity
/ Antiviral Agents - administration & dosage
/ Cancer
/ Diseases
/ Hemorrhagic Fever, Ebola - drug therapy
/ High-Throughput Screening Assays
/ Humans
/ Leukemia
/ Liver
/ Medicine
/ Medicine and Health Sciences
/ T cells
/ Toxicity
/ Viruses
